Stock Events

Stock Events

Corcept Therapeutics 

€35.56
0
-€0.46-1.28% Friday 19:55

Statistics

Day High
36.31
Day Low
35.27
52W High
76.94
52W Low
27.74
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q4 2025
Next
-0.09
0.03
0.16
0.28
Expected EPS
-0.092690832
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HTD.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes in the pharmaceuticals space, focusing on therapies that could directly compete with Corcept's treatments in endocrine and metabolic diseases.
Pfizer
PFE
Mkt Cap161.09B
Pfizer operates in various therapeutic areas, including endocrinology, potentially competing with Corcept's hormone-related therapies.
Merck
MRK
Mkt Cap298.84B
Merck is involved in developing medications for a wide range of conditions, including those that could compete with Corcept's focus areas.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb develops drugs in multiple therapeutic areas, including those that could compete with Corcept's products in hormonal and metabolic diseases.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a broad portfolio of drugs, including treatments for endocrine disorders, directly competing with Corcept's market.
AMGEN
AMGN
Mkt Cap187.56B
Amgen focuses on innovative therapeutics, including endocrine and metabolic disorders, which could compete with Corcept's therapies.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, known for its work in antiviral drugs, also explores treatments in other areas that could compete with Corcept's focus on metabolic and endocrine disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals focuses on developing drugs for a wide range of diseases, including potential competition in the endocrine and metabolic disorder space.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, potentially including those that compete with Corcept's niche in hormonal therapies.

About

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Joseph K. Belanoff M.D.
Employees
730
Country
United Kingdom
ISIN
US2183521028

Listings

MI
IT
1CORT.MI
STU
DE
HTD.STU
MU
DE
HTD.MU
BOATS
BOATS
CORT.BOATS

0 Comments

Share your thoughts

FAQ

What is Corcept Therapeutics stock price today?▼
The current price of HTD.STU is €35.56 EUR — it has decreased by -1.28% in the past 24 hours. Watch Corcept Therapeutics stock price performance more closely on the chart.
What is Corcept Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Corcept Therapeutics stocks are traded under the ticker HTD.STU.
Is Corcept Therapeutics stock price growing?▼
HTD.STU stock has fallen by -3.37% compared to the previous week, the month change is a +27.41% rise, over the last year Corcept Therapeutics has showed a -40.87% decrease.
When is the next Corcept Therapeutics earnings date?▼
Corcept Therapeutics is going to release the next earnings report on May 06, 2026.
What were Corcept Therapeutics earnings last quarter?▼
HTD.STU earnings for the last quarter are 0.17 EUR per share, whereas the estimation was 0.28 EUR resulting in a -39.3% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Corcept Therapeutics have?▼
As of April 12, 2026, the company has 730 employees.
In which sector is Corcept Therapeutics located?▼
Corcept Therapeutics operates in the Other sector.
When did Corcept Therapeutics complete a stock split?▼
Corcept Therapeutics has not had any recent stock splits.
Where is Corcept Therapeutics headquartered?▼
Corcept Therapeutics is headquartered in Redwood City, United Kingdom.